Q-omics provides the consensus-scored KCTD9 profile across patient tissues and cancer cell-line models. KCTD9 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KCTD9 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, KCTD9 RNA expression shows 19,725 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where KCTD9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD9 survival associations across molecular data types. KCTD9 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD9 RNA expression–survival associations across cancer types. High KCTD9 expression shows unfavorable associations in BLCA, LGG, LUAD, LIHC and KICH, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KCTD9 RNA expression.
This table summarizes KCTD9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KCTD9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD9 shows lower tumor expression in COAD, THCA, BRCA and LUAD and higher tumor expression in KIRC and KIRP. The COAD box plot shows higher KCTD9 RNA expression in normal versus tumor tissue (log2 FC = −1.493, t-test p < 0.001).
This table shows molecular features associated with KCTD9 in patient tissues and cancer cell lines. In patient samples, KCTD9 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCTD9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
